Zydus Lifesciences' heart rhythm disorder drug approved by USFDA

Apixaban blocks the activity of certain clotting substances in the blood.

FPJ Web Desk Updated: Tuesday, February 28, 2023, 08:54 PM IST
Image: Zydus (Representative)

Image: Zydus (Representative)

According to an exchange filing, Indian pharma firm Zydus Lifesciences, has received final approval from the United States Food and Drug Administration (USFDA) for Apixaban Tablets, 2.5 mg and 5 mg . Apixaban blocks the activity of certain clotting substances in the blood.

It is used to lower the risk of stroke or a blood clot in people with a heart rhythm disorder called atrial fibrillation. It is also used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery.

It is also used for treatment of blood clots in the veins of legs or lungs, and reduces the risk of them occurring again. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad

Published on: Tuesday, February 28, 2023, 08:54 PM IST

RECENT STORIES